Código QR (código de barras bidimensional)

Real-World Outcomes of First-Line Pembrolizumab Monotherapy in Metastatic NSCLC with High PD-L1 Expression (TPS ≥ 50%): A Multicenter Study from Serbia

<b>Background:</b> Pembrolizumab monotherapy is the standard first-line treatment for metastatic non-small cell lung cancer (NSCLC) patients whose tumors express a PD-L1 tumor proportion score (TPS) of ≥50%. However, real-world data regarding its effectiveness outside of clinical trials, particularl...

全面介紹

Na minha lista:
Principais autores: Filip Marković, Mihailo Stjepanović, Milan Rančić, Marina Cekić, Milica Kontić
格式: Artigo
語言:Inglês
出版: MDPI AG 2025-05-01
叢編:Biomedicines
主題:
first-line
high PD-L1 expression
immune check-point inhibitors
non-small cell lung cancer
pembrolizumab
predictive factors
在線閱讀:https://www.mdpi.com/2227-9059/13/5/1175
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍